Pharma Update

Columvi + Polivy + R-CHP in 1L DLBCL early data encouraging Building upon POLARIX to address remaining unmet need Ph I study design Roche COLUMVI glofitamab POLIVYⓇ polatuzumab vedotin Cycle 1 Cycle 2 Cycle 3-6 Glofit* Glofit+ Glofit+ Pola* Pola* Pola* R R R D8 D15 D8 CHP CHP CHP 21-day DLT window *Pola-R-CHP administered on D1 of each 21-day cycle (maximum 6 cycles); *Glofitamab IV administered in C2-C6, C2 SUD (2.5mg C2D8, 10mg C2D15); target dose (30mg) C3D8 onwards Patient characteristics • 24 patients enrolled, received study treatment** Median age 65.0 years Majority of patients had a high tumor burden Endpoint assessment criteria Response rate assessed by PET-CT 1 Key inclusion criteria Aged ≥18 years, ECOG PS 0-3, IPI score 2-5 • Encouraging Ph I data with Columvi + Polivy + R-CHP demonstrating high CMR rates, irrespective of baseline IPI score, no patients had progressive disease Initiating treatment with Polivy + R-CHP (debulking) was associated with a low rate and mild severity of CRS (3 patients with G1 CRS only) • More mature data to be presented at upcoming conference . Ph III Columvi + Polivy+ R-CHP in 1L DLBCL to be initiated 2023 Dickinson M. et al., ASCO 2023; **as of November 14, 2022; 1. Cheson BD, et al. J Clin Oncol 2014;32:3059-68; R=Rituximab; CHP-Cyclophosphamid, doxorubicin and prednison; DLBCL-Diffuse large B-cell lymphoma; PET-CT-Positron emission tomography-computerized tomography; CRS-Cytokine release syndrome; ECOG Eastern Cooperative Oncology Group performance status; IPI=International Prognostic Index; DLT-Dose-limiting toxicity; IV=Intravenous; CMR=Complete metabolic response; G1-Grade 1; D=Day 92

View entire presentation